Breaks Categories: Stock Spotlights

MondayFeb 06, 2017 1:17 pm

NetworkNewsBreaks – Aytu Bioscience, Inc.’s (AYTU) MiOXSYS® Platform Addresses Diagnostic Challenges of Male Infertility

Oxidative stress is known to be a contributing factor to male infertility, though a significant amount of infertility cases remain unexplained. This is largely due to a lack of standardized tests to determine oxidative stress. A new clinical application called MiOXSYS®, however, is set to change that by assessing oxidative stress levels in semen as an aid in the diagnosis of male infertility. The platform is being developed by Aytu BioScience (OTCQX: AYTU), a leading pharmaceutical company focusing on the commercialization of innovative urology products. The company is currently pursuing regulatory approval for commercialization in the United States while boosting…

Continue Reading

MondayFeb 06, 2017 1:15 pm

NetworkNewsBreaks – Newtek Business Services Corp. (NASDAQ: NEWT) Embraces E-Commerce as Growing Payment Trend

As a business development company, Newtek Business Services (NASDAQ: NEWT) is focused on providing financial and business services to the small- and medium-sized business market. Through its electronic payment processing, managed technology solutions, small business finance, and Capcos segments, Newtek has helped increase revenues, reduce expenses and minimize risks for over 100,000 business accounts. Newtek’s electronic payment and eCommerce solutions portfolio companies processed $4.7 million in sales for its eCommerce merchants on Black Friday 2016, a substantial 12.6% increase over Black Friday the year prior. To learn more, visit www.newtekone.com About Newtek Business Services Corp. Newtek Business Services Corp., Your…

Continue Reading

MondayFeb 06, 2017 11:20 am

NetworkNewsBreaks – FDA Grants Small Business Status to Cytori (NASDAQ: CYTX)

Cytori (NASDAQ: CYTX) has been granted Small Business status for fiscal year 2017 by the U.S. Food and Drug Administration Division of Industry and Consumer Education. The designation allows Cytori to receive substantial financial incentives, fee reductions, and fee waivers for selective FDA medical device regulatory filings. The company is also eligible for a substantial reduction in many medical device user fees and a one-time waiver of the user fee for its first premarket approval (PMA) application, potentially occurring later in 2017. “Cytori Cell Therapy benefits from being regulated as a device through the PMA process. The small business designation…

Continue Reading

MondayFeb 06, 2017 11:15 am

NetworkNewsBreaks – Rosetta Genomics (NASDAQ: ROSG) Receives Two U.S. Patent Allowances for RosettaGx Reveal™ microRNAs

Rosetta Genomics (NASDAQ: ROSG) shares are nudging higher after the company said the U.S. Patents and Trademark Office has granted two patent allowances for divisional patents of the parent application titled “microRNAs and uses thereof.” The company said the patents are important markers for its RosettaGX Reveal™ thyroid cancer assay, as this strengthens its intellectual property portfolio and provides opportunities for monetization. “We are creating a strong intellectual property position in microRNAs and thyroid cancer diagnostics. Of note, there are approximately 500 peer-reviewed publications that confirm the effectiveness of microRNAs as biomarkers in the diagnosis of thyroid cancer which makes…

Continue Reading

FridayFeb 03, 2017 3:44 pm

NetworkNewsBreaks – Soligenix, Inc.’s (NASDAQ: SNGX) SGX301 Receives Promising Innovative Medicine Designation in the UK; Aegis Capital Increases PT to $7

Shares of Soligenix (NASDAQ: SNGX) continued to climb Friday following the company’s announcement yesterday that its SGX301 was granted Promising Innovative Medicine (PIM) designation in the United Kingdom by the Medicines and Healthcare Products Regulatory Agency for the treatment of cutaneous T-cell lymphoma. The PIM designation is the first step toward inclusion in the Early Access to Medicines Scheme (EAMS), which provides severely ill patients with life-threatening and seriously debilitating conditions early access to groundbreaking new medicines - before marketing authorization is approved. "This is now the second of our programs to receive this important designation, with the first being…

Continue Reading

FridayFeb 03, 2017 12:15 pm

NetworkNewsBreaks – FDA Accepts Filing of Intellipharmaceutics’ (NASDAQ: IPCI) NDA for Rexista™; Aegis Reiterates ‘Buy’ Rating and $8 PT

Shares of Intellipharmaceutics International (NASDAQ: IPCI) are slightly higher following news late yesterday that the FDA has accepted the company’s filing of a New Drug Application (NDA) for Rexista™ for the management of moderate to severe pain. Pivotal pharmacokinetic and abuse-deterrent studies have shown Intellipharmaceutics’ Rexista as bioequivalent to OxyContin®. "The acceptance of filing of our NDA for Rexista™ represents an important step towards the commercialization of a potentially best–in-class abuse-deterrent oxycodone hydrochloride extended release product.  We look forward to working with the FDA during their review of our NDA submission," Intellipharmaceutics CEO Dr. Isa Odidi stated in the news…

Continue Reading

ThursdayFeb 02, 2017 12:27 pm

NetworkNewsBreaks – Check-Cap (NASDAQ: CHEK) Advances toward Regulatory Approval of Colonoscopy Alternative, C-Scan®

Check-Cap (NASDAQ: CHEK) is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the screening of precancerous polyps and cancer. The company’s C-Scan® system provides an alternative to the current Colorectal Cancer (CRC) screenings, such as a colonoscopy, to help increase screening rates. Unlike a colonoscopy, Check-Cap’s system doesn’t require a bowel prep, which is a huge selling point for at-risk patients. Check-Cap recently enrolled the first patient in its multi-center study of the C-Scan® system in support of its plans to submit for a CE Mark in the first…

Continue Reading

ThursdayFeb 02, 2017 12:21 pm

NetworkNewsBreaks – Propanc Health Group Corp. (PPCH) Continues to Advance Pipeline of Anti-Cancer Products

Propanc (OTCQB: PPCH) is a development-stage health care company working to advance its pipeline of new and proprietary treatments for cancer patients suffering from solid tumors toward clinical trials. The company recently issued an update on the progress of additional pending patent applications, noting that it had received a written opinion from the International Search Authority regarding a recent Patent Cooperation Treaty application filed in Australia. The majority of claims in the written opinion were considered novel and inventive, as determined by the authorized officer from the Australian Patent Office. The company’s patent application in Spain, titled "Cancer Treatment," was…

Continue Reading

ThursdayFeb 02, 2017 12:18 pm

NetworkNewsBreaks – Sunworks, Inc. (NASDAQ: SUNW) Shares Nudge Higher on Patent for 3D Solar Cell Technology

Sunworks (NASDAQ: SUNW) is trading higher following word that the solar company was granted a patent for its 3D solar cell technology. Issued by the Chinese Patent Office, the patent is titled 'Three-Dimensional Power Systems and Methods of Making Same'. According to the news release, the patented cell collects sunlight from wider angles and causes light to bounce within its 3-dimensional microstructure. The process continues until the cell is fully absorbed, thereby maximizing the rate of conversion from sunlight to electricity. Sunworks also recently entered into a partnership with Ecoark Holdings (OTCQX: EARK), a technology company that develops supply chain…

Continue Reading

ThursdayFeb 02, 2017 10:49 am

NetworkNewsBreaks – Vanguard Natural Resources (NASDAQ: VNR) Files for Chapter 11 Protection; Shares Tumble

Vanguard Natural Resources (NASDAQ: VNR) shares dropped more than 60% in early trade after the company announced it has voluntarily filed petitions for Chapter 11 bankruptcy.  In addition, the company has entered into a Restructuring Support Agreement with certain consenting holders of the company's 7.875% Senior Notes due 2020, 8 3/8% Senior Notes due 2019 and 7.0% Senior Secured Second Lien Notes due 2023. Vanguard said it intends to use this agreement to eliminate approximately $708 million in debt under its reserve-based credit facility and senior unsecured debt. "We continue to believe in the quality of our asset base and…

Continue Reading